Sarepta Therapeutics announced last month a collaboration with University College London for the development of an exon-skipping drug targeting
exon 53, its fourth drug in development, in support of Sarepta’s broad-based program for the treatment of Duchenne muscular dystrophy (DMD)
If you want minimal results, resolve to do the bare minimum. If you want surprising results--results that set tongues to wagging and produce spikes in your stock price--you’ll need to think "outside of the box."
For everyone’s sakes, we have to stay on the ball and be ready to
jump in and lend a helping hand at any moment. The microbes don’t really care who we are or where we live.
In recent years, significant work has been dedicated to
studying the half-life of drugs, and while researchers have been successful in lengthening the half-life of proteins and peptides, they have yet to find a
way to tailor the pharmacokinetics of certain drugs to specific medical needs.”
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.